Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient

Autor: L. Liaudet, C. Padoin, M. Rusca, Thierry Buclin, O. Marchetti, C. Robatel
Jazyk: angličtina
Rok vydání: 2004
Předmět:
Microbiology (medical)
Antifungal Agents
Fatal Outcome
Pharmacokinetics
Sieving coefficient
Aged
Antifungal Agents/blood
Antifungal Agents/pharmacokinetics
Area Under Curve
Chromatography
High Pressure Liquid
Female
Half-Life
Hemofiltration
Humans
Kidney Failure
Chronic/metabolism
Kidney Failure
Chronic/therapy
Pneumonia
Pneumocystis/complications
Pneumonia
Pneumocystis/drug therapy
Pyrimidines/blood
Pyrimidines/pharmacokinetics
Respiratory Distress Syndrome
Adult/complications
Respiratory Distress Syndrome
Adult/drug therapy
Triazoles/blood
Triazoles/pharmacokinetics
Medicine
Pharmacology (medical)
Dosage adjustment
Pharmacology
Voriconazole
Respiratory Distress Syndrome
business.industry
Critically ill
Pneumonia
Pneumocystis
Total body
Disposition
Triazoles
Single patient
Infectious Diseases
Pyrimidines
Anesthesia
Kidney Failure
Chronic
business
medicine.drug
Zdroj: The Journal of Antimicrobial Chemotherapy, vol. 54, no. 1, pp. 269-270
Popis: Objectives: To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF). Methods: Voriconazole pharmacokinetics were studied in a critically ill patient under CVVHDF. The analysis was carried out for 12 h following a 6 mg/kg dose. Voriconazole concentrations were measured by HPLC in blood inlet and outlet lines and in dialysate. Results: The total body clearance of voriconazole was 20.3 L/h, with a terminal half-life of 13.7 h and a distribution volume of 399 L. The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h. Conclusions: CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment.
Databáze: OpenAIRE
Externí odkaz: